The overall aim of the research is to advance in a decisive way how we predict, evaluate and prevent the onset and progression of type 1 diabetes (T1D).
This will be achieved by creating novel tools, such as biomarkers, disease models and clinical trial paradigms. These tools will allow us to distinguish and understand at the cellular and molecular level distinctive paths of ontogeny and progression in this heterogeneous disease, thus impacting on the future management of T1D patients and at risk individuals.
1. INNODIA (Translational approaches to disease modifying therapy of type 1 diabetes: An innovative approach towards understanding and arresting type 1 diabetes)
Aim: To advance our understanding of prediction, staging, evaluation and prevention of the onset and progression of type 1 diabetes.
Collaborators: 26 academic partners, 4 EFPIA partners, 1 SME partner, and 2 public organizations
2. Biomarker discovery
Aim: To identify biomarkers that predicts T1D risk, progression and treatment/intervention response. The research combines genetics, genomics, metabolomics studies with phenotypically well-characterized cohorts.
Collaborators: Dept. Pediatrics, HGH, other clinical sites, Cornell Med School, NY, ULB, Brussels, UVA, Charlottesville
3. AniGen – Animal genomes as models for human health
Aim: To establish a resource for optimal selection of the best animal model for studying specific aspects of human disease
Collaborators: University of CPH, LEO Pharma
4. Epigenetics and Type 1 Diabetes
Aim: To study the role of epigenetics as a risk factor for T1D development
Collaborators: SSI, University of Lund